Structural and metabolic topological alterations associated with butylphthalide treatment in mild cognitive impairment: Data from a randomized, double‐blind, placebo‐controlled trial

• DOI: 10.1111/pcn.13812
• Publication Date: 2025-04-01T07:54:42Z
• Authors: Xiaodong Han; Shuting Gong; Jin Gong; Pin Wang; Ruina Li; Runqi Chen; Chang Xu; Wenxian Sun; Shaoqi Li; Yufei Chen; Yuting Yang; Heya Luan; Boye Wen; Jinxuan Guo; Sirong Lv; Cuibai Wei

Aims Effective intervention for mild cognitive impairment (MCI) is key preventing dementia. As a neuroprotective agent, butylphthalide has the potential to treat MCI due Alzheimer disease (AD). However, pharmacological mechanism of from brain network perspective not clear. Therefore, we aimed investigate multimodal changes associated with treatment in AD. Methods A total 270 patients AD received either or placebo at ratio 1:1 1 year. was defined as decrease Alzheimer's Disease Assessment Scale‐Cognitive Subscale (ADAS‐cog) > 2.5. Brain networks were constructed using T1‐magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. support vector machine applied develop predictive models. Results Both (drug vs. placebo)‐time interactions efficacy (effective ineffective)‐time detected on some overlapping structural metrics. Simple effects analyses revealed significantly increased global efficiency under both effective butylphthalide. Among metrics, an degree centrality left paracentral lobule related poorer improvement. The model based baseline metrics exhibited high accuracy (88.93%) predicting butylphthalide's efficacy. Conclusion Butylphthalide may restore abnormal organization AD, could be markers therapeutic Clinical Trial Registration This study registered Chinese Registry (Registration Number: ChiCTR1800018362, Date: 2018‐09‐13).